Fig. 5. Overall survival (A) and disease-free survival (B) of FB-GBC and NC-GBC after propensity score matching (n = 148). Even after adopting propensity score matching, the survival outcomes between the two groups were still significantly different; the 5-year overall survival rate (74.3% vs. 44.1%, p = 0.002) and disease-free survival rate (58.3% vs. 21.6%, p < 0.001) were lower in the NC-GBC group. FB-GBC, gallbladder cancer in the fundus/body; NC-GBC, gallbladder cancer in the neck/cystic duct; 5-YSR, 5-year survival rate.